Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06680830 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
A Phase 2 study of Parkinson Disease and Parkinson, sponsored by Neuron23.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06680830: Recruiting Phase 2 study of Parkinson Disease and Parkinson, sponsored by Neuron23.
NCT06680830 is a Phase 2 study of Parkinson Disease and Parkinson that is actively recruiting participants, run by Neuron23. The registered enrollment target is 150 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06680830, a Phase 2 study of Parkinson Disease and Parkinson, is actively recruiting participants, sponsored by Neuron23.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG NEU-411
Study Locations (20)
California
- Neuro-Pain Medical Center - Fresno
- University of California, Irvine - Irvine
- University of California, Los Angeles - Los Angeles
- Esperanza Clinical - Murrieta
- Parkinson's Research Centers of America - Palo Alto - Palo Alto
- Sutter Neuroscience Institute - Sacramento
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- University of Florida - Gainesville
- Neurology One - Orlando
- USF Parkinson's & Movement Disorders Clinic - Tampa
Georgia
- Emory University - Atlanta
- Augusta University - Augusta
Arizona
- Banner Sun Health Research Institute - Sun City
Arkansas
- University of Arkansas - Little Rock
Colorado
- University of Colorado - Anschutz Medical Campus - Aurora
Illinois
- Northwestern Medical Group, Department of Neurology - Chicago
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-01-17 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06680830 shows while recruiting
NCT06680830 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06680830 names 20 study sites across 11 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06680830 about?
NCT06680830 is a clinical study titled "A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease". The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic pr...
What is the current status of trial NCT06680830?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-01-17. Estimated completion is 2027-09.
What conditions does trial NCT06680830 study?
This clinical trial studies the following conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Parkinson Disease, Idiopathic, Early Parkinson Disease (Early PD).
What interventions are being tested in trial NCT06680830?
The interventions under investigation include: Placebo (OTHER), NEU-411 (DRUG).
Who is sponsoring clinical trial NCT06680830?
This trial is sponsored by Neuron23, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06680830 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06680830's enrollment target sits among peer trials
150 54th of 297 higher than 243 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI